Growth in UK surgical trials: strengthening the evidence behind innovation

A reported expansion

The number of surgical randomised controlled trials funded by the UK’s National Institute for Health and Care Research (NIHR) rose from 34 in 2011 to 188 in 2023, according to Digi24’s report citing The Economist. Digi24 places those figures within a wider discussion about the evidence supporting surgical procedures, including concerns about interventions that may be unnecessary or cause more harm than benefit.

For surgeons interested in technology and innovation, the reported increase offers a starting point for discussing comparative research. It may signal greater attention to testing surgical interventions, but the figures alone do not establish whether particular procedures or technologies are effective, or whether the reported growth has changed clinical practice.

What the figures capture

The figures reported by Digi24 concern NIHR-funded surgical randomised controlled trials. They should not be read as a count of all surgical research undertaken in the UK. It is not yet clear from the information available how trials were counted, whether the totals describe active studies or another funding measure, or how consistently the categories were applied across the two years.

Those distinctions matter when interpreting the scale of the reported change. Without further detail, it is not yet clear whether the increase reflects a broader range of research questions, more studies within existing areas, changes in recording, or some combination of factors. The reported totals cannot resolve those possibilities on their own.

Questions for innovation

Digi24’s account, citing The Economist, connects the trial figures with the wider issue of evidence for surgery. For an innovation-focused readership, that connection raises questions rather than providing a verdict on any individual intervention: what was compared, which outcomes were studied, and how closely did the research address the procedure or technology under discussion?

It is not yet clear which specialties, procedures or technologies account for the reported increase. Nor is it clear how many of the trials reached completion or published results. These gaps limit what can be inferred about the evidence available for any specific innovation. A larger reported trial count is not, by itself, an answer to a question about a particular intervention.

Activity and impact

The growth reported by Digi24 is a measure of trial activity as described in its account, rather than a reported measure of improved patient outcomes. The available information does not establish whether the additional trials supported existing approaches, challenged them, or produced findings that remained uncertain.

Similarly, Digi24’s wider discussion of potentially unnecessary or harmful procedures should not be taken to mean that every intervention included in the reported trial totals falls into those categories. It is not yet clear how that wider discussion relates to the individual NIHR-funded studies.

An open evidence question

The central point reported by Digi24, citing The Economist, is the increase between the two dates. Its significance for surgical innovation remains an open question beyond those totals. A fuller picture would include the subjects studied, the comparisons made, the results reported and any subsequent changes in practice. Until those details are clear, the figures offer a prompt for discussion, not a verdict on surgical innovation.

This article is an overview for information only; readers should consult the original sources and appropriate professional guidance.